XBiotech Announces Publication of Positive Clinical Results for Xilonix™ in Non-Small Cell Lung Cancer

Apr 1, 2015 AUSTIN, Texas , April 1, 2015 / PRNewswire / -- XBiotech Inc., a leading developer of next-generation True Human™ therapeutic antibodies, announced today that results from a subset of non-small cell lung cancer (NSCLC) patients treated in a study of the Company's lead True Human antibody, Xilonix™, conducted at MD Anderson Cancer Center in Houston, TX , will be published in an upcoming edition of Investigational New Drugs . The article is currently available online 1 . The results highlight a potential synergy of Xilonix anti-IL-1alpha therapy in NSCLC patients previously treated with EGFR inhibitors. As reported in Investigational New Drugs , NSCLC patients with metastatic, refractory disease at baseline were treated with Xilonix monotherapy until disease progression. In addition to assessment of radiographic evidence of tumor response, changes in lean body mass, and quality of life, patients were followed for 24 months to assess survival. Radiographic evidence of anti-tumor effect was observed, in addition to improvements in lean body mass and quality of life. Furthermore, stratification by prior therapies revealed a median overall survival for patients treated with anti-EGFR therapy of 9.4 months compared to only 4.8 months for non-pretreated patients. Dr. Michael Stecher , the Company's Medical Director added, "As a patient's disease progresses, resistance of the tumor to therapy becomes more common. Some of this resistance may be due to the immunosuppressive effects of inflammation in the tumor microenvironment. The suggestion that Xilonix therapy may help overcome this resistance is highly encouraging and warrants further exploration in non-small cell lung cancer and other tumor indications." About XBiotech XBiotech is a leading developer of next-generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development. 1 2015. Hong, David S. et al., Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs , dx.doi.org/10.1007/s10637-015-0226-6 . Contact: Ashley Otero XBiotech [email protected] 512.386.2930 Tiberend Strategic Advisors : Joshua Drumm , Ph.D. (investors) [email protected] (212) 375-2664 Amy Wheeler (media) [email protected] (646) 362-5750 Logo - http://photos.prnewswire.com/prnh/20150312/181290LOGO To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/xbiotech-announces-publication-of-positive-clinical-results-for-xilonix-in-non-small-cell-lung-cancer-300059682.html SOURCE XBiotech Medicine should make you feel better, not worse Modern medicine should help patients feel better, not worse. At XBiotech, we believe in the Hippocratic principle of "do no harm." We believe this is inherent to the innovative True Human™ antibody medicines we are developing. True Human™ antibodies move beyond the idea that effective medicines must come with toxicity or harmful side effects. By utilizing the body’s natural immune system, XBiotech develops therapies that help you heal and feel better. Contact Us Contact Us XBiotech’s True Human™ antibodies are derived from individuals with natural immunity to disease. Extra links Technology Technology Pipeline Pipeline Clinical Clinical News News About About Investor Investor Our contacts Call: (512) 386-2900 (512) 386-2900 Fax: (512) 386-5505 (512) 386-5505 [email protected] [email protected] 5217 WINNEBAGO LN. AUSTIN 5217 WINNEBAGO LN. AUSTIN Search © XBiotech USA, INC. . All Rights Reserved 2026

The release as fetched from its publisher. xbiotech.com ↗